期刊文献+

浸润性乳腺癌MRI弥散加权成像ADC值与分子表达之间的相关性分析 被引量:1

Correlation analysis between ADC value and molecular expression in diffusion-weighted MRI of invasive breast cancer
下载PDF
导出
摘要 目的 分析浸润性乳腺癌表观扩散系数(ADC)与雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)、P53表达之间的相关性。方法 收集2016年1月至2021年11月福建省宁德市闽东医院穿刺或手术病理确诊为浸润性乳腺癌患者114例的MRI检查及病理检查资料,分析MRI检查中浸润性乳腺癌形态学改变(边缘毛刺征)、强化特点以及ADC值与ER、PR、HER-2以及P53之间的相关性。结果 浸润性乳腺癌病灶在T1WI、fs T2WI多呈低或等信号,增强扫描早期多表现为由边缘向中心逐渐强化,边缘多有毛刺征。114例乳腺癌病灶DWI均为高信号,ADC图上为低信号,b值越高,病灶ADC值越低,差异有统计学意义(P <0.05)。免疫组化提示ER、PR、HER-2以及P53阳性率分别为80.70%、37.72%、65.79%和47.37%。边缘毛刺征的浸润性乳腺癌患者ER、PR、HER-2以及P53阳性检出率比较,差异无统计学意义(P> 0.05)。增强扫描早期不均匀强化的浸润性乳腺癌患者HER-2阳性检出率高于均匀强化特点者,差异有统计学意义(P <0.05)。b=800及1000 s/mm^(2)时,HER-2阳性检出患者ADC值高于阴性者,b=1000 s/mm^(2)时,P53阳性检出患者ADC值高于阴性检出者,差异有统计学意义(P <0.05)。b=800及1000 s/mm^(2)时,ADC值与HER-2阳性表达之间呈正相关(P <0.05),b=1000 s/mm^(2)时,ADC值与P53表达之间呈正相关(P <0.05)。结论 浸润性乳腺癌患者的ADC值与HER-2及P53蛋白阳性表达之间存在一定的关系,提示从影像角度评估乳腺癌生物学行为及预后具有一定的可行性。 Objective To analyze the correlation between the apparent diffusion coefficient(ADC)and the expression of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2(HER-2),and P53 in invasive breast cancer.Methods The MRI and pathological examination data of 114 cases of invasive breast cancer diagnosed by puncture or surgical pathology in Mindong Hospital of Ningde City,Fujian Province from January 2016 to November 2021 were collected.The morphological changes(marginal spiculation),enhancement characteristics and the correlation between ADC value and ER,PR,HER-2 and P53 in invasive breast cancer were analyzed.Results Most of the invasive breast cancer lesions showed low or equal signals on T1WI and fs T2WI.In the early phase of enhanced scanning,the lesions were gradually enhanced from the edge to the center,and the edges were often spiculated.In 114 cases of breast cancer,the DWI of the lesions showed a high signal,with a low signal on the ADC map.The higher the b value,the lower the ADC value of the lesion,with a statistically significant difference(P<0.05).The immunohistochemical results showed that the positive rates of ER,PR,HER-2,and P53 were 80.70%,37.72%,65.79%,and 47.37%,respectively.The positive rates of ER,PR,HER-2 and P53 in invasive breast cancer patients with marginal spiculation were compared,without statistically significant differences(P>0.05).The positive rate of HER-2 in invasive breast cancer patients with uneven enhancement at the early stage of enhanced scanning was higher than that in patients with homogeneous enhancement,with a statistically significant difference(P<0.05).When b=800 s/mm2 and 1000 s/mm2,the ADC value of HER-2 positive patients was higher than that of negative patients.When b=1000 s/mm2,the ADC value of P53 positive patients was higher than that of negative patients,with a statistically significant difference(P<0.05).When b=800 s/mm2 and 1000 s/mm2,there was a positive correlation between ADC value and HER-2 positive expression(P<0.05),and when b=1000 s/mm2,there was a positive correlation between ADC value and P53 expression(P<0.05).Conclusion There is a certain relationship between ADC value and HER-2 and P53 protein-positive expression in patients with invasive breast cancer,which suggests that it is feasible to assess the biological behavior and prognosis of breast cancer from the perspective of imaging.
作者 姜剑榕 陈芳 黄清存 曾凤仙 JIANG Jianrong;CHEN Fang;HUANG Qingcun;ZENG Fengxian(Department of Radiology and Imaging,Mindong Hospital of Ningde City,Fujian,Fu'an 355000,China)
出处 《中国医药科学》 2023年第17期160-164,共5页 China Medicine And Pharmacy
关键词 浸润性乳腺癌 表观扩散系数 雌激素受体 孕激素受体 人表皮生长因子-2 P53 Invasive breast cancer Apparent diffusion coefficient Estrogen receptor Progesterone receptor Human epidermal growth factor receptor-2 P53
  • 相关文献

参考文献10

二级参考文献112

  • 1李宏斌.ADC联合DCE-MRI对乳腺癌诊断价值[J].中华肿瘤防治杂志,2019,26(S01):43-43. 被引量:7
  • 2张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 4Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 6Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 7Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 8Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 9Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 10Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.

共引文献775

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部